NEWS : CIMS Healthcare Excellence Awards 2017- Best Hospital Unit in Oncology & Individual Excellence in the field of Operations * Padmashree Dr. Ramakant Deshpande, Executive Chairman and Director of ACI, receiving an award for the Best Healthcare Entrepreneur at Global Awards for Excellence in Quality Management & Leadership * ACI DAYCARE-BORIVALI 4 Feb launching of centre by the hands of cabinet Minister Shree Vinod Tawde & sitting MP Shree Gopal Shetty * Click Here To Take Appointment!!! * We have Sucessfully performed 250 Robotic Surgery till date *
BLOG : Afatinib Superior to Erlotinin Liquid Biopsy gives 100% accuracy Head and Neck New Urinary Molecular Test

Recently details of the LUXLung 8 phase 3 trial became available. This study compared afatinib with erlotinib as second-line treatment for squamous cell carcinoma of the lung.

Afatinib was better with respect to all parameters – median progression-free survival, overall survival and patient-reported quality of life outcome (using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 LC13).

Rates of improved global health status/quality of life (35.7% vs 28.3%; P = .041) and cough (43.4% vs 35.2%; P = .029) were significantly greater with afatinib than erlotinib.?
Afatinib significantly delayed time to deterioration of dyspnea versus erlotinib (2.6 vs 1.9 months; P = .008), with a trend toward delayed time to deterioration of cough with afatinib.

Changes in mean scores over time favored afatinib over erlotinib significantly for cough (P = .0091), dyspnea (P = .0024), and pain (P = .0384).

This is how we improve quality of life and survival for patients with lung cancer.

Left Menu Icon